Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous disorder having a wide range of clinical phenotypes, and is currently classified into "typical CIDP" and variants, such as multifocal acquired demyelinating sensory and motor neuropathy. Typical CIDP is clinically characterized by symmetric polyneuropathy involving proximal as well as distal muscle weakness, whereas electrophysiology shows evidence of demyelination predominant in the distal nerve terminals, and magnetic resonance neurography frequently shows prominent hypertrophy of the nerve roots. The pattern of demyelination distribution strongly suggests primary involvement of the nerve terminals and roots, where the blood-nerve barrier is anatomically deficient, and the importance of an antibody-mediated mechanism. In contrast, multifocal acquired demyelinating sensory and motor neuropathy is multiple mononeuropathy or asymmetric polyneuropathy with multifocal conduction blocks and focal nerve enlargement in the intermediate nerve trunks at the site of conduction block; such distribution of lesions is reasonably explained by breakdown of the blood-nerve barrier by activated lymphocytes, suggesting a multiple sclerosis-like cellular mechanism. Clinical features are likely to be determined by the immunopathogenesis, and therefore different immunological treatment would be required for each CIDP subtype. The present review focuses on current concepts of the disease spectrum of "CIDP syndrome" deciphered by electrophysiology and neuroimaging.
Introduction
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neuropathy, and should be considered in any patients with symmetric or even asymmetric polyneuropathy progressive for more than 2 months. 1, 2 The diagnosis of CIDP is defined on clinical symptoms and signs, electrodiagnostic studies, and other laboratory tests.
1 Therefore CIDP is a heterogeneous disorder having a wide range of clinical phenotypes, course, pathogenesis and response to immunotherapy. 2 In the Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society (EFNS/PNS), CIDP is classified into clinical subtypes:
1 classical CIDP is termed as "typical CIDP"; and another variant, "atypical CIDP," includes multifocal acquired demyelinating sensory and motor neuropathy (MADSAM) or asymmetric CIDP (Lewis-Sumner syndrome), distal acquired demyelinating symmetric neuropathy (DADS), and focal or pure motor/sensory CIDP (Table 1) . These CIDP variants are still categorized as CIDP, but have distinct clinical and laboratory features, and presumably a different pathogenesis. All the subtypes of CIDP share a common feature -acquired peripheral nerve demyelination -but the distribution of demyelinating lesions is somewhat different among each subtype of CIDP, particularly in typical CIDP and MADSAM, and it is proposed that the distribution patterns of demyelination determine the clinical phenotypes. 2, 3 It is established that electrophysiology can provide important information on how demyelination is distributed along the longitudinal course of a nerve; in nerve conduction studies, changes in waveforms of distally-evoked compound muscle action potentials (CMAP; e.g. prolonged distal motor latency and increased duration or polyphasia of distal CMAP) indicate demyelination in the motor nerve terminals, whereas partial motor conduction blocks reflect demyelination in the nerve trunk between the stimulus sites (e.g. the forearm segments of the median and ulnar nerves). 3 Separately, neuroimaging studies using magnetic resonance imaging (MRI), as well as ultrasound of nerves, are becoming increasingly important in the diagnosis and evaluation of peripheral neuropathies. In particular, MR neurography has an excellent soft tissue contrast and sensitivity to pathology. [4] [5] [6] Previous studies have shown nerve enlargement in the nerve roots, brachial or lumbosacral plexus, and nerve trunks using T2-weighted or short tau inversion recovery images. However, conventional MRI provides images of only restricted regions of the peripheral nerves. In 2015, we developed reconstruction MR neurography -3-D reconstruction short tau inversion recovery images to visualize from the nerve roots to the more peripheral segments of nerve trunks. 7 This technique clearly showed longitudinal morphological changes from the cervical roots to the nerve trunks in the proximal arm or thigh. Among the CIDP subtypes, typical CIDP patients showed symmetric and root-dominant hypertrophy, whereas MADSAM patients had multifocal fusiform hypertrophy in the nerve trunks. The patterns of nerve enlargement are very consistent with electrophysiological findings, the combination of electrophysiology and MR neurography providing specific patterns of nerve involvement to each CIDP subtype. 7 The present review focuses on the clinical-electrophysiological-neuroimaging correlation in the subtypes of CIDP, and proposes a hypothesis that typical CIDP and MADSAM neuropathy are respectively caused by antibody-and cell-mediated mechanisms. Our previous review published in this journal emphasized the concept solely based on electrophysiological findings and response to treatment. 2 Data in recent neuroimaging studies support the hypothesis.
Frequency of CIDP subtypes
A number of studies have reported the frequency of subtypes of CIDP in patients who fulfilled EFNS/PNS diagnostic criteria. A study from France has showed that of 146 patients, 51% suffered typical CIDP, and 15% had MADSAM. 8 In a report from the UK, 46
CIDP patients had sensorimotor symmetric (probably typical CIDP; 80.4%), MADSAM (15.2%) or DADS (6.5%). 9 Of our Japanese CIDP cohort (n = 100), 60% had typical CIDP, 36% had MADSAM and 5% had DADS. The frequency of CIDP subtypes is somewhat different among the studies, presumably because there are no established criteria for classification of the subtypes; particularly for MADSAM, how asymmetric is asymmetric is not rigorously defined. In our previous study, the diagnosis of MADSAM was defined as typical mononeuropathy multiplex or asymmetry of symptoms, which was determined as differences in muscle strength by one or more Medical Research Council scales in the homonymous muscles at the initial examination. 3 Whereas proper criteria should be developed in future studies, the major subtype of CIDP is typical CIDP (50-80% of patients who fulfilled the EFNS/ PNS criteria), and the second frequent subtype is MADSAM (15-36%).
Additionally, pure motor or sensory CIDP is still controversial. The definition of pure sensory CIDP has not been established; most of the reported patients with clinically sensory-predominant or pure sensory CIDP showed definite demyelinating motor nerve conduction abnormalities that were required for the diagnosis of CIDP. Furthermore, even if neuropathy is clinically pure sensory, motor weakness develops during the course of the disease. DADS neuropathy is a rare subtype constituting 5% of total CIDP patients.
Typical CIDP
A prominent clinical feature of typical CIDP is the presence of both proximal and distal muscle weakness. Such patterns of weakness are also frequently seen in a demyelinating form of Guillain-Barr e syndrome (acute inflammatory demyelinating polyneuropathy). The distal nerve terminals and nerve roots, where the blood-nerve barrier is anatomically deficient, 10 are preferentially affected by demyelination in typical CIDP and acute inflammatory demyelinating polyneuropathy, 11, 12 and demyelination predominant in the most distal and proximal parts of a nerve would explain the "non-nerve length-dependent" distribution of muscle weakness in typical CIDP, because these regions can be involved irrespective of the nerve length. We speculate that in the early stage of typical CIDP, the nerve terminals/ roots would be selectively affected, and activation of complements and upregulated inflammatory cytokines could result in gradual expansion of demyelination to the nerve trunk during the long course of CIDP. Figure 1a shows findings of medial motor nerve conduction studies in a patient with typical CIDP. Distal motor latency is prolonged (7.1 ms; normal <4.1 ms), and distal CMAP duration is prominently increased (10.5 ms; normal <5.9 ms), indicating demyelination distal to the wrist, probably in the distal motor nerve terminals. 13 Distal CMAP amplitude decreased (1.9 mV; normal >5.0 mV), presumably because of distal conduction block, whereas CMAP changes between the wrist and axilla is relatively mild, and nerve conduction velocity is preserved (41 m/s, normal >47 m/s). Almost all patients with typical CIDP show such a pattern of nerve conduction abnormalities. Because distal nerve segments are severely affected, information of the proximal nerve segments cannot be assessed by electrophysiology. However, prominent nerve root hypertrophy is present in the same patient (Fig. 1a, right column) . Notably, nerve hypertrophy is less prominent in the nerve trunk in the proximal arm segment. Symmetric and root-dominant nerve enlargement is observed in 86% of typical CIDP patients ( Table 2 ). The pathology of nerve hypertrophy in CIDP has not been fully understood, but an autopsy study has suggested that proliferation of the interstitial connective tissues and onion bulb formation might contribute to nerve enlargement.
14 In addition, it is possible that nerve edema associated with inflammation is partly responsible for nerve enlargement. The total clinical, electrophysiological and neuroimaging findings strongly suggest antibodymediated demyelination and macrostructural Figure 1 Representative waveforms of median nerve conduction studies and magnetic resonance neurography in a patient with (a) typical chronic inflammatory demyelinating polyneuropathy (CIDP) or (b) multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy.
changes (root hypertrophy). Pathogenetic antibodies preferentially access the nerve terminals/roots, where the blood-nerve barrier is deficient, and as the disease progresses, breakdown of the barrier leads to gradual involvement of the intermediated nerve trunks (Fig. 2a) . 15 Target molecule(s) in typical CIDP has not been identified, but we believe that autoantibodies against myelin or Schwann cells have a major role in the pathogenesis of typical CIDP. From the view of treatment, favorable response to immunoglobulin therapy and plasmapheresis supports the importance of the antibody-mediated mechanism(s). Furthermore, in the diagnosis of typical CIDP, nerve conduction studies and MR neurography are complementary, respectively detecting demyelinating lesions in the distal nerve segments and nerve roots.
MADSAM neuropathy
In 1982, Lewis and Sumner reported five patients presenting mononeuropathy multiplex with partial motor nerve conduction blocks in the intermediate nerve trunks (e.g. forearm in the media/ulnar nerves) as a variant of CIDP. 16 Later, Saperstain et al. described 11 patients with similar features, which were termed as MADSAM neuropathy or Lewis-Sumner syndrome. 17 Different from multifocal motor neuropathy, MADSAM patients had sensory nerve involvement and prominent demyelination in sural nerve biopsies. Since then, MADSAM has been regarded as an asymmetrical variant of CIDP.
MADSAM neuropathy patients usually show multiple mononeuropathy, but during the long course of the disease, they often develop asymmetric polyneuropathy. Therefore, the "asymmetry" of the clinical symptoms/signs might be less evident in the advanced stage, and the features can be similar to those of DADS. Electrophysiology of MADSAM is considerably different from that of typical CIDP, characterized by multifocal nerve conduction blocks in the intermediate nerve trunks. MADSAM patients do not show nerve terminal lesions and therefore distal CMAP are normal, unless associated with Wallerian degeneration, particularly in patients with long disease duration. 3 The lack of primary demyelination in the distal nerve terminals and the presence of focal lesions in the nerve trunk in MADSAM are distinct electrophysiological features from those of typical CIDP. Figure 1b shows the representative findings in median nerve conduction studies of a MADSAM patient. Distal latency and the amplitude of distal CMAP are normal, but prominent conduction block in the forearm segment is present, suggesting focal demyelination in the forearm segment of the median motor nerve. As described above, distribution patterns of demyelinating lesions assessed by electrophysiology are substantially different in typical CIDP and MADSAM. 2, 3, 18 In the same patient, MR neurography shows multifocal fusiform nerve enlargement, entirely different from the findings of typical CIDP. Figure 2b shows schema of the relationship between the blood-nerve barrier and demyelinating lesions in MADSAM. Hypertrophic nerves show gadolinium enhancement at the time of clinical relapse. 4 We speculate that an initial event could be the breakdown of the barrier; activated lymphocytes disrupt the barrier, invade the nerve parenchyma and cause cell-mediated attack leading to demyelination. The process could share the common pathophysiology that occurs in multiple sclerosis, and we therefore propose that MADSAM is a peripheral nerve version of multiple sclerosis. 3 
DADS and other subtypes of CIDP
In 2000, Katz et al. described 53 patients with chronic acquired demyelinating neuropathy with distal-dominant sensorimotor features. 19 In 70% of the patients, serum immunoglobulin (Ig)M monoclonal protein (M-protein) was present, and anti-myelin-associated glycoprotein antibodies were positive in 67% of the patients. The phenotype is currently classified as DADS. It is established that this disorder in seropositive patients is mediated by IgM anti-myelin-associated glycoprotein antibodies. 20 Given the large molecular weight of IgM (approximately 800 000), the antibodies cannot access the nerve trunk because of the blood-nerve barrier, and presumably bind to the distal nerve terminals, resulting in marked prolongation of distal latencies in nerve conduction studies. 21 The situation is similar to those of typical CIDP, but patients with DADS show distal-dominant sensory loss and motor weakness; the mechanisms for the distal-dominant manifestation have not been elucidated, but impaired axo-glial interaction and the resulting Wallerian degeneration might explain the pathophysiology and distal-dominant features.
More recently, anti-neurofascin-155 and anti-contactin-1 IgG4 antibodies were identified in a subgroup of DADS patients. 22 Patients with these antibodies are characterized by severe neuropathy, poor response to immunoglobulin therapy and disabling tremor. Neurofascin and contactin are paranodal proteins that act as adhesion molecules in the paranodal terminal myelin loops. The pathophysiology of CIDP with these antibodies is unknown, and future studies are required for the pathogenesis, again possibly impairing axo-glial interaction and Wallerian degeneration.
Other CIDP subtypes include pure motor or sensory CIDP, but it is still controversial whether pure motor symmetric CIDP and pure sensory CIDP really exist. Previous studies reported patients with pure sensory CIDP in which electrophysiological studies showed selective involvement of sensory nerve roots proximal to the dorsal root ganglion. 23 Such cases might correspond to pure sensory CIDP in the EFNS/ PNS guideline. However, the possibility that such patients represent dorsal root ganglionitis cannot be excluded. Systematic future studies are required to define pure sensory or motor CIDP.
Therapeutic implications
We propose that typical CIDP is an antibodymediated disease, and MADSAM neuropathy is mainly caused by a cell-mediated mechanism. If that is the case, response to immune modulation treatments should be different in typical CIDP and MAD-SAM. So far, studies on responsiveness to treatment for each CIDP subtype are limited, but some reports suggest that immunoglobulin therapy is efficacious in 87% of typical CIDP patients and just 38% of MADSAM patients, whereas corticosteroids were similarly effective (83% versus 72%). 3 A recent clinical trial of fingolimod reduced the amount of lymphocytes to the target regions, but failed to show efficacy in typical CIDP, and this is consistent with our hypothesis. Conversely, lymphocyte suppression could be indicated for MADSAM, and disease-modifying treatments used for multiple sclerosis, such as interferon-b, fingolimod and natalizumab, could be treatment options for MADSAM.
Conclusions
The current concept of CIDP includes several subtypes. Based on the findings of electrophysiology and neuroimaging, clinical features and subtypes are likely to be determined by the distribution of demyelinating lesions and the blood-nerve barrier. The different phenotypes probably indicate the different immunopathogenesis. Typical CIDP predominantly affects the regions where the blood-nerve barrier is deficient, which implies an importance of antibody-mediated mechanism(s). MADSAM type CIDP mainly involves the nerve trunk through cellular immunity with breakdown of the blood-nerve barrier. Future studies should focus on the pathogenesis and optimal treatment for each subtype of CIDP, and this will be further elucidated by a multidisciplinary approach using electrophysiology, neuroimaging and neuroimmunology.
